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ABSTRACT 40 
The gastrointestinal phenotype of cystic fibrosis (CF) features intestinal bile acid (BA) 41 
malabsorption, impaired intestinal farnesoid X receptor (FXR) activation and consequently 42 
reduced fibroblast growth factor 19 (FGF19, FGF15 in mice) production. The osmotic 43 
laxative polyethylene glycol (PEG) has been shown to decrease intestinal mucus 44 
accumulation in CF mice and could, by doing so, improve BA reabsorption. Here we 45 
determined the effect of PEG on BA excretion and FXR-FGF15 signaling in CF mice. Male 46 
Cftr-/-tm1Unc (CF) and wild type (WT) littermates were administered PEG 4000 in drinking 47 
water and fed either chow or a semisynthetic diet. PEG was withdrawn for three days 48 
before termination. Fecal BA excretion was measured at PEG dosages of 37 g/L (100%) 49 
and 0 g/L (0%). Ileal FXR activation was assessed by gene expression of its downstream 50 
targets Fgf15 and Shp. In CF mice, PEG withdrawal increased fecal BA excretion on either 51 
diet as compared to full PEG dosage (chow, 2-fold, p=0.06; semisynthetic, 4.4-fold, 52 
p=0.007). PEG withdrawal did not affect fecal BA excretion in WT mice on either diet. After 53 
PEG withdrawal, gene expression levels of intestinal FXR target genes Fgf15 and Shp 54 
were decreased in CF mice, but unaffected in WT littermates. PEG did not affect the gene 55 
expression of the main intestinal BA transporter ASBT. PEG treatment ameliorates 56 
intestinal BA malabsorption in CF mice and restores intestinal FXR-FGF15 signaling, 57 
independently from Asbt gene expression. These findings highlight the potential of PEG in 58 
the prevention and treatment of the gastrointestinal phenotype of CF. 59 
 60 
New & Noteworthy: A gastrointestinal feature of cystic fibrosis is bile acid malabsorption 61 
and consequent impairment of FXR-FGF15 signaling. FXR-FGF15 signaling regulates 62 
various metabolic processes and could be implicated in metabolic and gastrointestinal 63 
complications of cystic fibrosis, such as diabetes and liver disease. In cystic fibrosis mice, 64 
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treatment with the osmotic laxative polyethylene glycol is associated with decreased fecal 65 
bile acid loss and restoration of FXR-FGF15 signaling. 66 
 67 
Keywords: cystic fibrosis, bile acids, FXR, FGF15, polyethylene glycol 68 
69 
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INTRODUCTION 70 
Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the 71 
CFTR gene. CFTR functions as an ion channel to regulate chloride and bicarbonate 72 
transport and water volume on epithelial surfaces (25). In CF, reduced CFTR function in 73 
the epithelia of mucin-producing organs leads to the accumulation of viscous mucus, 74 
which promotes obstruction, infection and inflammation (12). Although the main cause of 75 
death in CF is lung disease (25), metabolic and gastrointestinal manifestations are 76 
becoming more frequent due to increased life expectancy thanks to improved treatment of 77 
pulmonary complications. The most prominent metabolic complication is CF-related 78 
diabetes mellitus (CFRD), affecting one third of patients (16). The CF gastrointestinal 79 
phenotype is characterized by obstruction, microbial dysbiosis and inflammation (21). 80 
Gastrointestinal complications include meconium ileus in the first days of life, as well as 81 
malnutrition in infancy. Exocrine pancreatic insufficiency and various degrees of CF-82 
related liver disease (CFLD) mostly ensue during childhood. As patients age, abdominal 83 
pain, constipation and the more severe distal intestinal obstruction syndrome (DIOS) 84 
further decrease their quality of life (25). Impairment of gut health affects numerous 85 
processes in the body (34). In CF, intestinal dysbiosis and subsequent chronic low-grade 86 
inflammation are linked to gastrointestinal malignancies, CFLD, CFRD, osteoporosis, and 87 
increased cardiovascular risk (19). Improving gut health in CF may thus improve several 88 
complications of this multiorgan disease. 89 
The gastrointestinal phenotype of CF is further characterized by increased fecal loss of 90 
bile acids (BA) in both patients (24) and CF mouse models (3, 4, 6, 11, 36). BAs are 91 
synthesized by the liver and secreted into the duodenum, where they aid in fat absorption. 92 
Under physiological conditions, ~95% of secreted BAs are reabsorbed by the small 93 
intestine, mostly via the apical sodium-dependent bile acid transporter (ASBT, SLC10A2), 94 
to be returned to the liver and thereby complete the enterohepatic circulation (18). In CF, 95 
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intestinal reabsorption of BAs is impaired, resulting in increased fecal BA loss (3, 4, 6, 11, 96 
24, 36). Besides their role in fat absorption, BAs exert important metabolic effects, mainly 97 
via the BA-sensing farnesoid X receptor (FXR) and its target fibroblast growth factor 19 98 
(FGF19 in humans, FGF15 in mice) (18). Upon reabsorption, BAs activate FXR in ileal 99 
enterocytes, resulting in FGF15/19 production. FGF19 travels to the liver via portal blood 100 
to exert negative feedback on BA synthesis (18). In CF, BA malabsorption and possibly 101 
other mechanisms result in defective FXR-FGF19 signaling, as suggested by reduced ileal 102 
Fgf15 mRNA levels in mice (8) and reduced serum FGF19 in patients (28). In patients, 103 
reduced FGF15/19 levels are associated with high fasting plasma glucose and type 2 104 
diabetes (10). In lean mice, Fgf15 deficiency resulted in glucose intolerance and 105 
diminished hepatic glycogen storage (17). Additionally, FGF19 administration protects 106 
against sclerosing cholangitis (38) and steatosis (39), lesions similar to those observed in 107 
CFLD. Impaired FXR-FGF19 signaling may therefore be implicated in the development 108 
and/or progression of CF complications such as CFLD and CFRD. Thus, restoring BA 109 
homeostasis in CF is an attractive avenue to improve CF complications. 110 
The mechanism underlying BA malabsorption in CF is unclear, however two 111 
hypotheses prevail. Firstly, the thickened intestinal mucus layer could impair the 112 
translocation of BAs from the lumen to the epithelium for their reabsorption. Secondly, 113 
intestinal dysbiosis could promote bacterial BA deconjugation and thereby decrease BA 114 
reabsorption, as ASBT preferentially transports conjugated rather than deconjugated BAs 115 
(13). Moreover, CF-mediated changes in ASBT expression or functionality could be 116 
involved. Some of the factors mentioned in these hypotheses were improved in CF mice 117 
upon treatment with the osmotic laxative polyethylene glycol (PEG) (22). PEG is routinely 118 
administered to mice lacking Cftr expression to prevent development of lethal intestinal 119 
obstruction (7). PEG decreased mucus accumulation in the small intestine, intestinal 120 
bacterial load, and the expression of certain inflammatory genes (22). We therefore 121 
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hypothesized that PEG treatment could improve the reabsorption of BAs in CF. In this 122 
study, we aimed to determine the effect of PEG treatment on BA malabsorption and FXR 123 
signaling in CF mice. Our results indicate that indeed PEG treatment is associated with 124 
decreased fecal BA loss, as well as increased FXR-FGF15 signaling. 125 
  126 





Male Cftr-/- (Cftrtm1UNC on a >99% C57BL/6 background, CF) mice (n=15) and wild-type 130 
(WT) littermates (n=15) aged 8-20 weeks obtained from an in-house breeding colony were 131 
housed individually under conventional (non-specific pathogen-free) housing conditions in 132 
a light- and temperature-controlled facility (12-hour light-dark cycles, 21°C) with ad libitum 133 
access to water and food. Two diets were used to account for outcome dependency on 134 
dietary factors. The mice received either chow [RM3 (E) FG, Special Diet Services, 135 
England; composition by proximate analysis: fat 4.3% (cholesterol 0.05%), protein 22.4%, 136 
fiber 4.2% (of which 25% cellulose, 57% hemicellulose, 9% pectin, and 9% lignin), 137 
nitrogen-free extract 51.2%), or a semisynthetic diet (No. 4063.02, AB diets, The 138 
Netherlands; composition: fat 5.2% (cholesterol 0.01%), protein 17.3%, fiber (100% 139 
cellulose) 10.5%, nitrogen-free extract 55.7%]. Animal experiments were approved by the 140 
Ethics Committee for Animal Experiments of the University of Groningen. All experiments 141 
were performed in accordance with relevant guidelines and regulations (including 142 
laboratory and biosafety regulations). 143 
 144 
Experimental procedures 145 
PEG (polyethylene glycol 4000 with electrolytes, Ipsen Farmaceutica, The Netherlands, 146 
containing, in g/l: 32 PEG 4000, 0.73 NaCl, 0.375 KCl, 0.84 NaHCO3, and 2.85 Na2SO4, 147 
tot. 37g/l) was administered via drinking water in decreasing concentrations. All mice, 148 
irrespective of their genotype, were administered PEG (37 g/l water) since weaning to 149 
prevent the intestinal obstruction often observed in these CF mice (7). On day 0, PEG 150 
dosage was decreased by 50% (18.5 g/l water) to determine the PEG-dependency of CF 151 
mice. On day 7, PEG treatment was stopped for three days until termination. Fecal pellets 152 
were collected over a 24-hour period before decreasing PEG dosage (day 0, 100% PEG) 153 
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and daily from day 8 to 10 (0% PEG). This procedure was followed for both groups, the 154 
one receiving chow (CF n=5, WT n=4) and the other receiving semisynthetic diet (CF n=3, 155 
WT n=5). Additionally, a separate group of mice (CF n=7, WT n=6) fed semisynthetic diet 156 
was administered PEG at full dosage (37 g/L water) until termination and was included for 157 
ileal gene expression only. Mice were anesthesized with isoflurane and euthanized by 158 
cervical dislocation. Terminal blood samples were collected in EDTA-coated tubes. 159 
Tissues were collected and immediately frozen in liquid nitrogen. 160 
 161 
Analytical methods 162 
Neutral sterol (NS) and bile acid (BA) analyses. NS and BAs were extracted and 163 
measured by gas chromatography (GC) as previously described (32). Total amounts were 164 
calculated as the sum of the individual species. BA species included: α-muricholic acid, β-165 
muricholic acid, chenodeoxycholic acid, cholic acid, deoxycholic acid, hyodeoxycholic acid, 166 
ω-muricholic acid and ursodeoxycholic acid. NS species included: cholesterol, coprostanol 167 
and dihydrocholesterol.  168 
Gene expression analysis. The small intestine was divided into three segments of equal 169 
length. Total RNA was isolated from mid-sections of the most distal of the three segments 170 
(ileum) with TRI-Reagent (Sigma, St. Louis, MO, USA) and quantified by NanoDrop 171 
(NanoDrop Technologies, Wilmington, DE, USA). Primers were designed using Primer-172 
BLAST and optimized for use with Hi-ROX SensiMixTM SYBR Green master mix (Bioline, 173 
Taunton, MA, USA). Primers used are listed in Table 1. Real-time qPCR analyses were 174 
performed on a StepOnePlusTM Real-Time PCR system (Applied Biosystems, Foster City, 175 
CA, USA). Gene expression levels were normalized to 36B4 (Rplp0). 176 
Gene Forward primer 5'---3' Reverse primer 3'---5' 
Fgf15 GCC ATC AAG GAC GTC AGC A CTT CCT CCG AGT AGC GAA TCA G 
Shp AAG GGC ACG ATC CTC TTC AA CTG TTG CAG GTG TGC GAT GT 
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Asbt ACC ACT TGC TCC ACA CTG CTT CCC GAG TCA ACC CAC ATC TT 
Gata4 GAG ATG CGC CCC ATC AAG GAC ACA GTA CTG AAT GTC TGG GAC AT 
Rplp0 CTG TTG GCC AAT AAG GTG CC GGA GGT CTT CTC GGG TCC TA 
Table 1 - qPCR primer sequences used in this study. 177 
 178 
Statistical analyses. GraphPad Prism v6.0 for Macintosh (GraphPad Software, La Jolla, 179 
CA, USA) was used for data analyses. We analyzed data using a mixed-model ANOVA 180 
with genotype as between-subjects factor, and PEG treatment as within-subjects factor 181 
using SPSS v25.0 for Windows IBM SPSS Statistics for Windows, Version 25.0 (IBM, 182 
Armonk, NY). Statistical differences were subsequently tested using the Student’s T-test 183 
for unpaired data and the paired T-test for paired data. For correlation analyses, 184 
Spearman’s rank correlation coefficient was used. Alpha was set at 0.05. In figures 1-4, 185 
data concerning 100% PEG dosage refers to 24-hour feces collected on day 0. Data 186 
concerning 0% PEG dosage represents the average of 24-hour feces collected on days 8, 187 
9 and 10. 188 
189 
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RESULTS  190 
 191 
PEG treatment ameliorates bile acid malabsorption in CF mice 192 
To investigate the effect of PEG on BA malabsorption in CF mice, PEG was reduced 193 
stepwise until complete withdrawal. All mice survived without signs of bowel obstruction or 194 
overt diarrhea. The body weight of CF mice tended to be lower than that of WT, however 195 
statistical significance was not reached (data not shown). The fecal output was higher in 196 
mice fed chow compared to mice fed the semisynthetic diet (Fig. 1A vs. 1B), despite 197 
similar food intake (data not shown). PEG withdrawal decreased the fecal output in WT 198 
mice on either diet (Fig. 1A,B), but not in CF mice. 199 
 200 
Figure 1. Effect of PEG on fecal output in WT and CF mice maintained on (A) chow and 201 
(B) semisynthetic diet. Data refers to dry fecal weight and was normalized to body weight. 202 
Data are presented as mean±SD, n=3-5. Data of WT mice was compared with that of CF 203 
mice by Student’s T test. Within-individual mouse changes in fecal output with 100% or 0% 204 
PEG treatments were compared by paired T test. PEG: polyethylene glycol. 205 
 206 
PEG withdrawal increased fecal BA excretion by two-fold in CF mice receiving a chow 207 
diet (Fig. 2A). In contrast, PEG withdrawal exerted little effect on the fecal BA excretion in 208 
WT mice (Fig. 2A). 209 
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In CF mice, there is high variability in the absolute amount of fecal BAs observed in 210 
previous studies (3, 4, 6, 11, 36), which might be related to the diet, genetic background or 211 
environmental factors. In a previous study, fecal BA excretion was lower in rats fed a 212 
semisynthetic diet compared to chow (14). To investigate dependency of the outcome on 213 
diet, we also performed the same experiment with a semisynthetic diet, which has a 214 
different fiber content and composition. Compared to the groups maintained on chow, 215 
mice receiving semisynthetic diet showed a 5-to-10-fold lower fecal excretion of BAs (Fig. 216 
2A vs. 2B). With PEG, fecal BA excretion was similar between CF and WT mice on a 217 
semisynthetic diet (Fig. 2B), whereas in those fed chow this was different between the 218 
genotypes (Fig. 2A). In CF mice fed a semisynthetic diet, PEG withdrawal increased fecal 219 
BA excretion by about 4-fold (Fig. 2B). As observed on chow, PEG did not affect fecal BA 220 
excretion in WT mice (Fig. 2B). These findings indicate that PEG improves BA 221 
malabsorption in CF mice, on either diet. 222 
 223 
Figure 2. Effect of PEG on fecal BA excretion in WT and CF mice maintained on (A) chow 224 
and (B) semisynthetic diet. Fecal BA excretion was determined by gas chromatography 225 
and normalized to body weight. Data are presented as mean±SD, n=3-5. Data of WT mice 226 
was compared with that of CF mice by Student’s T test. Potential changes in fecal BA 227 
excretion in individual animals, as a result of PEG withdrawal, were assessed by a paired 228 
T test.  229 
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 230 
PEG treatment does not affect fecal neutral sterol excretion 231 
Since BAs are essential for intestinal absorption of fat, including cholesterol, fecal 232 
neutral sterol (NS) excretion was determined (Fig. 3). This was lower in mice receiving 233 
semisynthetic diet as compared to chow (Fig. 3A vs. 3B). In WT mice on either diet, PEG 234 
withdrawal was associated with a decrease in fecal NS excretion (Fig. 3A,B). Fecal NS 235 
excretion was higher in CF as compared to WT mice fed chow, independent of PEG 236 
treatment (Fig. 3A). Upon semisynthetic diet, fecal NS excretion was similar between CF 237 
and WT mice and was unaffected by PEG in CF mice (Fig. 3B). We found a positive 238 
relationship between fecal BA and NS excretion (Fig. 3C). Interestingly, coprostanol, a 239 
cholesterol metabolite formed by intestinal microbial conversion, was only found in 1 out of 240 
8 mice fed a semisynthetic diet, whereas it was found in all mice of either genotype fed 241 
chow (data not shown). 242 
 243 


























































































rs = 0.86, 95%CI 0.73-0.93
p <0.0001
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Figure 3. Effect of PEG and diet on fecal neutral sterol (NS) excretion in WT and CF mice 244 
maintained on (A) chow and (B) semisynthetic diet. Fecal NS excretion was determined by 245 
gas chromatography and normalized to body weight. Data is presented as mean±SD, n=3-246 
5. Data of WT mice was compared with that of CF mice by Student’s T test. Within-247 
individual mouse changes in fecal NS excretion while receiving 100% or 0% PEG 248 
treatment were compared by paired T test. (C) Correlation plot between fecal NS excretion 249 
and fecal BA excretion, including data from Fig. 2A,B and Fig. 3A,B. For correlation 250 
analyses, Spearman’s rank correlation coefficient was used. PEG, polyethylene glycol. 251 
 252 
PEG treatment partly normalizes the fecal BA composition in CF mice 253 
The fecal BA composition is altered in CF patients and mice, in whom the contribution 254 
of the primary BA cholic acid (CA) is high and that of deoxycholate (DCA) is generally low 255 
(4, 33, 36). We also found that the contribution of CA to the fecal BA composition was 256 
substantially higher in untreated CF as compared to WT mice (Fig. 4), and this difference 257 
in CA contribution among the two genotypes was reduced by PEG treatment (Fig. 4). PEG 258 
treatment decreased the CA contribution in CF mice (Fig. 4). The contribution of the 259 
primary BA chenodeoxycholic acid (CDCA), a potent FXR activator, to the fecal BA 260 
composition, tended to be lower in untreated CF as compared to WT mice, and tended to 261 
be increased by PEG treatment in CF mice (Fig. 4). The contribution of β-muricholic acid 262 
(β-MCA) to the fecal BA composition was decreased in untreated CF as compared to WT 263 
mice, and was increased by PEG in CF mice (Fig. 4). Together, these findings indicate 264 
that PEG partially restored imbalances in the fecal BA composition in CF mice. In contrast 265 
with previous studies in CF and WT mice fed a liquid diet (4, 36), no fecal deoxycholic acid 266 
(DCA) was detected. 267 
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 268 
Figure 4. Effect of PEG on the fecal BA composition in mice fed semisynthetic diet. Data 269 
is shown as percentages of total fecal bile acids. Individual BA species were detected by 270 
gas chromatography. Bile acid species include: α-MCA, α-muricholic acid; CA, cholic acid; 271 
CDCA, chenodeoxycholic acid; β-MCA, β-muricholic acid; ω-MCA, ω-muricholic acid. n=3-272 
5. Data of WT mice was compared with that of CF mice by Student’s T test. Within-273 
individual mouse changes in fecal BA composition while receiving 100% or 0% PEG 274 
treatment were compared by paired T test. PEG, polyethylene glycol. 275 
 276 
PEG treatment restores FXR-FGF15 signaling in CF mice 277 
To investigate the effect of decreased fecal BA excretion on FXR signaling, we 278 
measured ileal gene expression levels of its downstream targets, Fgf15 and small 279 
heterodimer partner (Shp, NR0B2) in the ileum, where BA reabsorption is most 280 
pronounced. With PEG treatment, Fgf15 and Shp mRNA levels were similar between CF 281 
and WT mice fed a semisynthetic diet (Fig. 5A). In contrast, after PEG withdrawal, both 282 
Fgf15 and Shp expression were suppressed in CF compared to WT mice. This 283 
suppression was stronger in mice receiving chow (Fig. 5B,C). In WT mice, PEG treatment 284 
did not affect Fgf15 or Shp gene expression. We found a strong inverse correlation 285 
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between fecal BA excretion and Fgf15 expression and between fecal BA excretion and 286 
Shp expression, indicating that increased fecal BA excretion was associated with lower 287 
gene expression of the FXR target genes Fgf15 and Shp (Fig. 5D,E). No correlation was 288 
observed between CDCA levels and Fgf15 gene expression (data not shown). 289 
Interestingly, PEG had no major effect on the expression of the main intestinal BA 290 
transporter, Asbt. However, without PEG treatment, its expression tended to be lower in 291 
CF mice fed semisynthetic diet as compared to WT mice (Fig. 5A,C). The transcription 292 
factor Gata4, known to repress expression of Asbt (27), was unchanged in CF as 293 
compared to WT mice on both diets (Fig. 5A-C). Accordingly, we found no correlation 294 
between Asbt and Gata4 gene expression (data not shown). Additionally, no correlation 295 
was found between Asbt and Shp (data not shown). Together, these findings indicate that 296 
improvement of BA malabsorption in CF mice by PEG treatment is associated with 297 
restored FXR-FGF15 signaling independent of Asbt expression. 298 
 299 
Figure 5. Effect of PEG on ileal gene expression in WT and CF  mice (A) on 100% PEG 300 
treatment with semisynthetic diet, n=3-5 (B) on 0% PEG with chow, n=4-5 and (C) on 301 
100% PEG with semisynthetic diet, n=6-7. Primers used are listed in Table 1. Data are 302 
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normalized to the housekeeping gene Rplp0 (36B4) and are expressed relative to WT 303 
values. Data are shown as mean ± SE. (D) Correlation plot between fecal BA excretion 304 
and Fgf15 and (E) Correlation plot between fecal BA excretion and Shp. For correlation 305 
analyses, Spearman’s rank correlation coefficient was used. PEG, polyethylene glycol; 306 
Fgf15, fibroblast growth-factor 15; Shp, small heterodimer partner; Asbt, apical sodium-307 
dependent bile acid transporter; Gata4, GATA-binding factor 4. 308 
  309 
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DISCUSSION 310 
In this study we show that PEG treatment completely prevented BA malabsorption in 311 
CF mice fed a semisynthetic diet, whereas this was partially prevented on a chow diet. In 312 
concomitance with improved BA absorption, FXR-FGF15 signaling was restored in CF 313 
mice fed a semi-synthetic diet by PEG treatment. 314 
There are several mechanisms that can explain the decrease in fecal BA loss by PEG 315 
treatment. In CF, mucins remain abnormally aggregated, adhere strongly and accumulate 316 
on the epithelium (30). Such a thickened mucus layer could impair BA reabsorption by 317 
acting as a poorly penetrable barrier. PEG has previously been shown to reduce mucus 318 
accumulation in the intestine of CF mice (22) and could have therefore facilitated BA 319 
reabsorption in our study. Decreased intestinal transit time was proposed as underlying 320 
mechanism (22). We, however, did not assess the effect of PEG on mucus accumulation 321 
in intestinal crypts in the current study. 322 
Decreased ASBT-mediated BA reuptake in CF could also be responsible for BA 323 
malabsorption. This, however, was not supported by our data. Previous studies have 324 
shown changes in Asbt expression in CF mouse models, either decreased or increased 325 
expression (2, 8, 20). In the current study, expression tended to be lower in CF mice upon 326 
semisynthetic diet and was unchanged upon a chow diet, suggesting that dietary factors 327 
may influence Asbt expression. Intestinal FXR activation has been shown to inhibit Asbt 328 
expression via Shp (23). However, here, as well as in a previous study (8), Asbt 329 
expression in CF mice tended to be reduced concomitantly with reduced Shp, suggesting 330 
that the regulation of Asbt expression by FXR-SHP may not be pivotal in CF. Asbt 331 
expression is also affected by gut microbiota, which represses expression via the 332 
transcription factor Gata4 (26). We found no correlation between Asbt and Gata4 333 
expression. These findings suggest that other factors besides FXR and GATA4 regulate 334 
Asbt expression in CF. Whereas PEG treatment decreased fecal BA loss and restored 335 
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FXR-FGF15 signaling in CF mice, the ileal expression of Asbt was still decreased upon 336 
PEG treatment, indicating that the effects of PEG on BA homeostasis were not mediated 337 
by changes in Asbt expression. We cannot exclude, however, that ASBT protein function 338 
is compromised in CF and partially restored by PEG. 339 
 340 
Impaired FXR-FGF15 signaling in untreated CF mice is reflected in the fecal BA 341 
composition, where an increased contribution of CA observed by us and others (4, 33, 36) 342 
reflects increased hepatic BA synthesis, likely due to lack of inhibition by FGF15 signaling. 343 
PEG treatment was associated with restoration of FXR-FGF15 signaling in CF mice. Our 344 
finding that PEG reduced the contribution of CA to the fecal BA pool in CF mice could 345 
reflect the increased FXR-FGF15 signaling observed upon PEG treatment. The strong 346 
correlation between fecal BA excretion and Fgf15 and Shp expression suggests that FXR-347 
FGF15 signaling was restored by improved BA reabsorption. 348 
PEG could also have affected FXR-FGF15 signaling in CF by affecting the gut microbial 349 
composition (37). Microbiota-induced changes in the BA pool composition can modulate 350 
FXR stimulation, as microbiota-dependent BAs such as the secondary BA deoxycholic 351 
acid (DCA) are FXR agonists (31). Small intestinal bacterial overgrowth (SIBO) has been 352 
reported in CF mice fed a liquid diet (22), therefore increased BA deconjugation could be 353 
expected. Since ASBT preferentially transports conjugated rather than deconjugated BAs 354 
(13), greater fecal BA loss could be expected in CF mice with SIBO. PEG was shown to 355 
decrease SIBO in CF mice (22) and to decrease secondary BAs such as DCA in WT rats 356 
(37). Although in previous studies DCA was found in small amounts in the feces of WT and 357 
CF mice (4, 5), we could not detect any DCA or coprostanol (both microbial metabolites) 358 
upon semisynthetic diet, suggesting that the catabolic activity of the gut microbiota was 359 
decreased. This could be due to the fact that, although the semisynthetic diet contains 360 
cellulose, refined cellulose is digested poorly by the microbiota compared to cellulose 361 
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derived from dietary fiber, at least in humans (32). Furthermore, no correlation between 362 
fecal CDCA levels and Fgf15 gene expression was found, suggesting that the changes in 363 
FXR activation were not due to increased activation by CDCA. Together, these findings 364 
suggest that restoration of FXR-FGF15 signaling in CF mice occurred as a consequence 365 
of improved BA reabsorption upon PEG treatment, rather than microbiota-dependent 366 
changes in the BA composition that could have heightened FXR stimulation. 367 
 368 
In line with previous observations (14), we found that fecal BA excretion in both 369 
genotypes was up to 10-fold higher in mice receiving chow as compared to a 370 
semisynthetic diet. The macronutrient composition, including fat, was similar across the 371 
two diets used, although more simple rather than complex carbohydrates were found in 372 
the semisynthetic diet. The fiber content and composition, however, differed greatly. By 373 
proximate analysis, the semisynthetic diet contained 10.5% of fiber, consisting exclusively 374 
of cellulose. Chow contained 4.2% of fiber, composed of cellulose (25%), hemicellulose 375 
(57%), pectin (9%) and lignin (9%). In vitro binding of BAs by dietary fiber has been 376 
demonstrated. Cellulose, the sole fiber in the semisynthetic diet, does not bind BAs, 377 
whereas other fibers such as pectin and lignin do, to varying extents (35). Therefore, the 378 
higher fecal BA excretion observed in chow-fed mice could be due to the presence of BA-379 
binding fibers such as pectin and lignin in chow. Whereas we found an up to 10-fold 380 
increase in fecal BA excretion upon chow compared to semisynthetic diet, other studies 381 
reported 2-to-5-fold increases in fecal labelled cholate excretion upon chow compared to 382 
semisynthetic diet (14, 29). Besides the lack of BA-binding fiber, another mechanism that 383 
could contribute to the decreased fecal BA excretion upon semisynthetic diet compared to 384 
chow is a decrease in the microbial catabolic activity in the intestine upon feeding a 385 
semisynthetic diet. Our data show that upon semisynthetic diet there was a decrease in 386 
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coprostanol and complete lack of the secondary bile acid deoxycholic acid, suggesting that 387 
the microbial catabolic activity was decreased.  388 
Compared to semisynthetic diet, besides increased fecal loss of BAs upon chow, we 389 
also observed increased loss of fecal NS upon chow. This could be due to the higher 390 
cholesterol content in chow (0.05%) compared to semisynthetic diet (0.01%), to decreased 391 
cholesterol absorption upon chow due to increased fecal BA loss, or to binding of 392 
cholesterol by dietary fiber along with BAs. As for binding of BAs, binding of cholesterol by 393 
cellulose was reported as negligible (15). The strong correlation between fecal BA and NS 394 
excretion could reflect all mechanisms. However, since in CF mice PEG treatment did not 395 
affect fecal NS to the extent it affected fecal BA excretion, this suggest that the effect of 396 
cholesterol binding by dietary fiber and difference in cholesterol content in the diet 397 
contributes more to this correlation. 398 
 399 
Our study shows that, in CF mice, the osmotic laxative PEG is associated with 400 
decreased BA malabsorption and restoration of FXR-FGF15 signaling, independently from 401 
Asbt expression. PEG is the most commonly prescribed and most effective osmotic 402 
laxative for constipation (1) and, as constipation is common in CF and its incidence 403 
increases with age (9), CF patients are already frequently prescribed PEG. PEG is virtually 404 
free of important side effects at standard dosage (27). Besides its indication for 405 
constipation in CF, based on the evidence provided in CF mice so far, PEG could also be 406 
useful for reducing SIBO and the consequences of gut dysbiosis and inflammation in CF 407 
(22). Our study shows that FXR-FGF15 signaling can be restored by PEG in CF. Given the 408 
metabolic implications of FXR-FGF19/15 signaling, it remains to be established whether 409 
this could improve CF-related complications such as cystic fibrosis-related diabetes 410 
(CFRD) and cystic fibrosis-related liver disease (CFLD). 411 
 412 
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